These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 34147031)

  • 1. Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity.
    Maniakas A; Henderson YC; Hei H; Peng S; Chen Y; Jiang Y; Ji S; Cardenas M; Chiu Y; Bell D; Williams MD; Hofmann MC; Scherer SE; Wheeler DA; Busaidy NL; Dadu R; Wang JR; Cabanillas ME; Zafereo M; Johnson FM; Lai SY
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4652-e4665. PubMed ID: 34147031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.
    Schweppe RE; Pozdeyev N; Pike LA; Korch C; Zhou Q; Sams SB; Sharma V; Pugazhenthi U; Raeburn C; Albuja-Cruz MB; Reigan P; LaBarbera DV; Landa I; Knauf JA; Fagin JA; Haugen BR
    Mol Cancer Res; 2019 May; 17(5):1036-1048. PubMed ID: 30733375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
    Yan P; Su Z; Zhang Z; Gao T
    Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
    Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
    Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line.
    Hegedűs L; Rittler D; Garay T; Stockhammer P; Kovács I; Döme B; Theurer S; Hager T; Herold T; Kalbourtzis S; Bankfalvi A; Schmid KW; Führer D; Aigner C; Hegedűs B
    Pathol Oncol Res; 2020 Oct; 26(4):2523-2535. PubMed ID: 32591993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma.
    Henderson YC; Mohamed ASR; Maniakas A; Chen Y; Powell RT; Peng S; Cardenas M; Williams MD; Bell D; Zafereo ME; Wang RJ; Scherer SE; Wheeler DA; Cabanillas ME; Hofmann MC; Johnson FM; Stephan CC; Sandulache V; Lai SY
    J Clin Endocrinol Metab; 2021 Sep; 106(10):2962-2978. PubMed ID: 34120183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
    Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
    J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology.
    Pinto AT; Pojo M; Simões-Pereira J; Roque R; Saramago A; Roque L; Martins C; André S; Cabeçadas J; Leite V; Cavaco BM
    Endocrine; 2019 Nov; 66(2):288-300. PubMed ID: 31368081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.
    Wu H; Sun Y; Ye H; Yang S; Lee SL; de las Morenas A
    Pathol Oncol Res; 2015 Jul; 21(3):695-701. PubMed ID: 25588542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary squamous cell carcinoma of thyroid with a novel BRAF mutation and High PDL-1 expression: A case report with treatment implications and review of literature.
    Torrez M; Braunberger RC; Yilmaz E; Agarwal S
    Pathol Res Pract; 2020 Oct; 216(10):153146. PubMed ID: 32853962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.
    Sheng W; Chen Y; Gong Y; Dong T; Zhang B; Gao W
    Oncol Rep; 2016 Dec; 36(6):3387-3396. PubMed ID: 27779717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Squamous Cell Carcinoma of the Thyroid Has a Molecular Genetic Profile Distinct From That of Anaplastic Thyroid Carcinoma: A Whole Exome Sequencing and Gene Expression Profiling Study.
    Ye M; Guo Z; Xu J; Jin Y; He X; Ge M
    Am J Surg Pathol; 2024 Aug; 48(8):1024-1031. PubMed ID: 38775423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
    Yoo SK; Song YS; Lee EK; Hwang J; Kim HH; Jung G; Kim YA; Kim SJ; Cho SW; Won JK; Chung EJ; Shin JY; Lee KE; Kim JI; Park YJ; Seo JS
    Nat Commun; 2019 Jun; 10(1):2764. PubMed ID: 31235699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
    Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
    Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
    [No Abstract]   [Full Text] [Related]  

  • 18. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study.
    Deeken-Draisey A; Yang GY; Gao J; Alexiev BA
    Hum Pathol; 2018 Dec; 82():140-148. PubMed ID: 30075157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.
    Passaro C; Borriello F; Vastolo V; Di Somma S; Scamardella E; Gigantino V; Franco R; Marone G; Portella G
    Oncotarget; 2016 Jan; 7(2):1500-15. PubMed ID: 26625205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
    Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
    J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.